<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867200</url>
  </required_header>
  <id_info>
    <org_study_id>A109_02BE2106</org_study_id>
    <nct_id>NCT04867200</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers</brief_title>
  <official_title>An Open Label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-344&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1 Clinical Trial to evaluate the safety and pharmacokinetics in healthy adult&#xD;
      volunteers after administration of CKD-344.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt(Area Under Curve last) of CKD-344</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration time curve of CKD-344, from time zero up to the last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
    <description>The maximum concentration observed of CKD-344 over blood sampling time.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anticoagulant</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Reference drug(Lixiana 60 mg)&#xD;
Period 2: Test drug(CKD-344 60 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test drug(CKD-344 60 mg)&#xD;
Period 2: Reference drug(Lixiana 60 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixiana(D006)</intervention_name>
    <description>NOAC(Factor Xa inhibitor)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Reference Drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-344</intervention_name>
    <description>NOAC(Factor Xa inhibitor)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Test Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult volunteers aged ≥ 19 years&#xD;
&#xD;
          2. Weight ≥60kg, with calculated body mass index(BMI) of 18 to 30 kg/m2&#xD;
&#xD;
          3. Those who have no congenital diseases or chronic diseases and have no abnormal&#xD;
             symptoms or findings.&#xD;
&#xD;
          4. Those who are eligible for clinical trials based on laboratory (hematology, blood&#xD;
             coagulation, blood chemistry, serology, urinalysis) at screening.&#xD;
&#xD;
          5. Those who agree to contraception during the participation of clinical trial.&#xD;
&#xD;
          6. Those who voluntarily decide to participate and agree to comply with the cautions&#xD;
             after fully understand the detailed description of this clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who has a medical evidence or a history of clinically significant&#xD;
             gastrointestinal, cardiovascular, endocrine, pulmonary, hematological, infective&#xD;
             disease, renal, urinary, psychiatric, neurologic, skeletomuscular, immune, etc.&#xD;
&#xD;
          2. Those who have a history of gastrointestinal surgery except simple appendectomy and&#xD;
             hernia surgery.&#xD;
&#xD;
          3. Those who had taken prescription or nonprescription drugs within 10 days prior to the&#xD;
             first dose of investigational product.&#xD;
&#xD;
          4. Those who received investigational products or participated in bioequivalence tests&#xD;
             within 6 months before the first administration of clinical trial drugs.&#xD;
&#xD;
          5. Those who donated whole blood within 8 weeks or blood components within 4 weeks prior&#xD;
             to the first dose of the investigational product.&#xD;
&#xD;
          6. Those who exceed an alcohol and cigarette consumption than below criteria. A. Alcohol:&#xD;
             Man- 21 glasses/week, Woman - 14 glasses/week B. Smoking: 20 cigarettes/day&#xD;
&#xD;
          7. Those who exceeds 2 times the upper limit of the reference range of AST(or ALT) or 1.5&#xD;
             times the upper limit of the reference range of γ-GTP.&#xD;
&#xD;
          8. Those who have hypersensitivity to the drug or the drug ingredient, such as&#xD;
             anaphylactic reactions.&#xD;
&#xD;
          9. Those who have specific disease(e.g. severe bleeding disorder, severe renal/hepatic&#xD;
             disease, uncontrolled severe hypertension, etc.)&#xD;
&#xD;
         10. Those who were deemed inappropriate to participate in the study by the investigator.&#xD;
&#xD;
         11. Those who have a pregnant or nursing woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yook-Hwan Noh</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yook-Hwan Noh, M.D., PhD.</last_name>
    <phone>+82-70-4665-9174</phone>
    <email>yook.noh@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yook-Hwan Noh</last_name>
    <phone>+82-70-4665-9174</phone>
    <email>yook.noh@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H+ Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yook-HwanYook-Hwan Noh</last_name>
      <phone>+827046659174</phone>
      <email>yook.noh@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

